newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

  • Verrica Pharmaceuticals reported Q2 2026 total revenue of $5.9 million, including $5.1 million in U.S. YCANTH net product revenue.
  • Dispensed applicator units for YCANTH reached 19,626 in Q2 2026, representing a 28.3% sequential increase & a 46.1% year-over-year increase.
  • Topline data from the global Phase 3 program for common warts is expected in mid-2027, with patient dosing occurring in the COVE-2 & COVE-3 trials.
  • The company entered a credit facility agreement with an entity controlled by Chairman Paul B. Manning for up to $27.5 million.
  • Based on current operations & the new credit facility, the company estimates its cash runway will extend into 2028.
  • VP-315 Phase 2 data presented in May 2026 showed potential abscopal effects in treating basal cell carcinoma.
  • The company signed an exclusive agreement with Medomie Pharma Ltd. on July 21, 2026, for YCANTH commercial rights in Israel.
  • Q2 2026 net loss was $13.2 million ($0.62 per share), compared to a net income of $0.2 million in the same period in 2025.
  • Research & development expenses increased to $6.0 million in Q2 2026, primarily driven by costs for the common warts program.
  • A $1.7 million expense was recognized for a legal settlement regarding a 2022 class action suit.
  • Conference call to discuss results was scheduled for August 6, 2026, at 4:30 pm ET.